#China #Shanghai #antibody therapeutics #Qure Biotechnology #Efung Capital

QureBio Secures Nearly CNY 100 Million in Series C1 Funding

On June 5, 2025, Qure Biotechnology (Shanghai) Co., Ltd., known as QureBio, made headlines by completing a significant Series C1 funding round. This initiative, led exclusively by Efung Capital, has successfully raised close to CNY 100 million, which is approximately USD 14 million. The proceeds from this financing are aimed at accelerating QureBio's clinical trials, as the company strives to advance its pipeline of innovative antibody therapeutics in an increasingly competitive global arena.

Focus and Technological Expertise

QureBio is not just another player in the crowded biopharmaceutical space; it specializes in crafting bispecific and multispecific antibody and protein therapeutics tailored to tackle unmet medical needs. Particularly, the company targets diseases like cancer, autoimmune disorders, and various inflammatory conditions. Its proprietary technology platforms—including the I2T platform and both T-cell and NK-cell engager platforms—form the backbone of its promising pipeline, enabling it to develop therapies aimed at diseases previously deemed difficult to treat.

Notable Pipeline Developments

The highlight of QureBio's pipeline includes several key candidates making impressive strides:

• - Q-1802: This bispecific antibody, targeting Claudin18.2 and PD-L1, has received regulatory approval to launch clinical trials in China and the US. Enrollment for Phase II patients is nearing completion, and preparations for Phase III trials in China are well underway.
• - Q-1801: This bispecific antibody, targeting SIRPα and PD-L1, has secured approvals for clinical trials in both markets and is set to commence its clinical studies.
• - PD-1 Antibody-Cytokine Fusion: This innovative fusion protein acts as a PD-1 checkpoint inhibitor and cytokine modulator. It shows promising potential in addressing challenges faced by similar products from larger biopharmaceutical firms, positioning QureBio to seek partners for accelerated global development.

Strategic Alliances and Market Recognition

QureBio's advanced antibody engineering technology has garnered immense recognition within the industry. The company has successfully established collaborations with several notable biotechnology and pharmaceutical firms, including BRL Medicine, BioMap, Hengrui Pharma, and Precision Scientific. These partnerships not only strengthen QureBio's capabilities but also underscore its growing influence within the biopharmaceutical sector.

A Visionary Leadership

Xiangdong Qu, the founder of QureBio, expressed gratitude towards Efung Capital for their continuing support and trust. He stated, "As an innovation-driven biotech enterprise focused on pioneering biopharmaceuticals, we aim to leverage our unique antibody technology platforms to develop revolutionary therapies for critical clinical needs, such as malignancies, autoimmune diseases, and inflammation-based disorders. We look forward to collaborating with various partners to bring these innovations to patients globally."

The lead investor from Efung Capital, Rongkui Fan, added that the Claudin18.2 bispecific antibody, as a model, holds the promise of delivering unique clinical value in gastric cancer's first-line therapy. Efung Capital remains optimistic about advancing Q-1802 into Phase III trials to provide innovative solutions for patients in need.

About QureBio and Efung Capital

Founded in 2017, Qure Biotechnology (Shanghai) Co., Ltd. has positioned itself as a biopharmaceutical innovator. Based in Shanghai, this company is committed to pioneering research and development of effective antibody and protein therapeutics focused on cancer, autoimmune diseases, and inflammatory disorders.

In contrast, Efung Capital is among the early professional biopharmaceutical investment firms in China, backed by a team of PhDs specializing in biopharmaceuticals from premier institutions both locally and internationally. Efung Capital focuses on global VC/PE investments within the biopharmaceutical landscape and is known for its diligent investment strategies and outstanding performance across various biotech sectors.

With this fresh influx of capital and an ambitious vision, QureBio is set to forge ahead, enhancing its clinical trials and expanding its pipeline to address pressing medical needs, making strides toward a promising future in biopharmaceutical innovation.